Sanofi can’t even buy a break now, as rival Novo speeds ahead on diabetes showdown
Things are just not going Sanofi’s way. Late last week, just a couple of days before Pfizer scooped out Medivation after slamming the French pharma’s bid to the sidelines, Sanofi had to concede that its application for a Lantus-plus-lixisenatide combo has been delayed. The FDA now plans to make a decision in November so it can take extra time to consider the fresh data it demanded to see.
Sanofi’s loss is Novo’s gain. The Danish pharma company looks to be on the inside track at the FDA after winning a unanimous vote at an agency panel review for Xultophy, its rival combination of Tresiba with its GLP-1 blockbuster Victoza.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.